Spleen Tyrosine Kinase Confers Paclitaxel Resistance in Ovarian Cancer.

Cancer cell ·Vol. 28 ·No. 1 ·2015-10-14

Wei Wei, Birrer Michael J

Abstract

Adaptive chemoresistance and consequent tumor recurrence present major obstacles to the improvement of the prognosis and quality-of-life of patients with advanced-stage ovarian cancer. In this issue of Cancer Cell, Yu and colleagues describe the critical role of spleen tyrosine kinase (SYK) in paclitaxel resistance by modulating the stability of microtubules.

Article Info

Journal

Cancer cell

Abbr.

Cancer Cell

ISSN

1535-6108

DOI

10.1016/j.ccell.2015.06.008

Published

2015-10-14

Indexed

2015-07-15

Updated

2015-11-19

Language

English

Country/Region

United States

NLM ID

101130617

External Links

PubMed source DOI: 10.1016/j.ccell.2015.06.008 View journal details

Analysis Services

Spleen Tyrosine Kinase Confers Paclitaxel Resistance in Ovarian Cancer.

Contact

WeChat Official Account